Literature DB >> 21178147

Recruitment of blood-derived inflammatory cells mediated via tumor necrosis factor-α receptor 1b exacerbates choroidal neovascularization.

Irina Semkova1, Philipp S Muether, Mark Kuebbeler, Klaus L Meyer, Norbert Kociok, Antonia M Joussen.   

Abstract

Purpose. Tumor necrosis factor (TNF)-α contributes to inflammation-associated angiogenesis, and TNF-α receptor 1b is selectively expressed on immuno-competent and endothelial cells. This study investigated the role of TNF-α receptor 1b in the recruitment of circulating inflammatory cells and the development of choroidal neovascularization (CNV). Methods. Lethally irradiated Tnfrsf1b(-/-) mice and their wild-type (WT) controls were transplanted with whole adult bone marrow (BM) cells, competent for both TNF-α receptors 1a and 1b (gfp(+) labeled), as well as with BM cells deficient for TNF-α receptor 1b. One month after transplantation CNV was induced by laser damage of Bruch's membrane. Pathologic angiogenesis was estimated qualitatively and quantitatively by histology on choroidal flatmounts and paraffin cross sections. Macrophage invasion was investigated by immunochemistry. Results. One month after transplantation the reconstitution rate measured by FACS analysis was >80% in gfp(+)-chimeric mice. Two weeks after laser injury reduced gfp(+)-cell invasion to the laser scars and decreased pathologic angiogenesis were observed in Tnfrsf1b(-/-) versus WT recipients. Approximately 70% of the invaded gfp(+) cells were labeled with macrophage marker F4/80. Transplantation of TNF-α receptor 1b-deficient BM cells in WT recipients reduced the CNV lesion compared with WT and Tnfrsf1b(-/-) recipients that received TNF-α receptor-competent BM cells. Transplantation of receptor 1b-deficient cells to Tnfrsf1b(-/-) recipients further reduced the degree of CNV formation. Conclusions. Signals through TNF-α receptor 1b expressed on BM -derived inflammatory cells mediate an increased inflammatory cell invasion and enhanced angiogenic response after laser-induced rupture of Bruch's membrane.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21178147     DOI: 10.1167/iovs.10-5996

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

1.  Lack of thrombospondin 1 and exacerbation of choroidal neovascularization.

Authors:  Shoujian Wang; Christine M Sorenson; Nader Sheibani
Journal:  Arch Ophthalmol       Date:  2012-05

2.  Innate Immunity in Age-Related Macular Degeneration.

Authors:  Yikui Zhang; Wai T Wong
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye.

Authors:  Hu Huang; Jikui Shen; Stanley A Vinores
Journal:  PLoS One       Date:  2011-06-22       Impact factor: 3.240

4.  Increased VEGF-A promotes multiple distinct aging diseases of the eye through shared pathomechanisms.

Authors:  Alexander G Marneros
Journal:  EMBO Mol Med       Date:  2016-03-01       Impact factor: 12.137

5.  VEGF receptor blockade markedly reduces retinal microglia/macrophage infiltration into laser-induced CNV.

Authors:  Hu Huang; Rachel Parlier; Ji-Kui Shen; Gerard A Lutty; Stanley A Vinores
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

6.  Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab.

Authors:  Anna Cardiakidis Myers; Fredrik Ghosh; Sten Andréasson; Vesna Ponjavic
Journal:  Curr Eye Res       Date:  2014-06-04       Impact factor: 2.424

Review 7.  Bone marrow-derived cells in ocular neovascularization: contribution and mechanisms.

Authors:  Fan Gao; Huiyuan Hou; Hongliang Liang; Robert N Weinreb; Haiyan Wang; Yusheng Wang
Journal:  Angiogenesis       Date:  2016-02-15       Impact factor: 9.596

8.  Porous silicon based intravitreal platform for dual-drug loading and controlled release towards synergistic therapy.

Authors:  David Warther; Ying Xiao; Fangting Li; Yuqin Wang; Kristyn Huffman; William R Freeman; Michael Sailor; Lingyun Cheng
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.